Krystal Biotech Inc (KRYS) Stock Price, Quote & News

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 586 5830

Website: www.krystalbio.com

Address:

2100 Wharton Street, Suite 701, Pittsburgh, United States

Iightning Dec. 4 at 4:57 AM

1ightning® Premium Options Alert (Actionable) Ticker: $KRYS Contract: Dec 19 $220C Entry: 5.80 Exit: 9.78 Return: +68.70% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 9:12 AM

1ightning® Premium Options Alert (Actionable) Ticker: $KRYS Contract: Dec 19 $270C Entry: 4.17 Exit: 5.80 Return: +38.90% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

macroaxis Dec. 3 at 12:25 AM

$KRYS - Krystal Options Alert: Put Open Interest Drops to 282.0 – Watch for Potential Volatility https://www.macroaxis.com/stock-options/KRYS/Krystal-Biotech?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

Iightning Dec. 1 at 11:10 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $KRYS **Contract:** Dec 19 $220C **Entry:** 7.50 **Exit:** 12.75 **Return:** **+70.01% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Ortho91 Nov. 28 at 12:12 PM

$KRYS rock on 🤘🏻

0 · Reply

Iightning Nov. 26 at 1:58 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:03 PM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:59 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

PolycarpFX Nov. 24 at 10:11 PM

Red Mile Group's latest holdings, one of the best biotech firms in the world I’ll be releasing my quarterly Biotech Report this week via my newsletter. $SRRK $KRYS $ZYME $IDYA

0 · Reply

Ortho91 Nov. 22 at 10:47 PM

$KRYS shorts are down 48% since 9/25🤣

0 · Reply

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 16, 2025, 9:00 AM EST - 18 days ago

Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth

Nov 3, 2025, 5:17 PM EST - 4 weeks ago

Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade)

Nov 3, 2025, 11:46 AM EST - 4 weeks ago

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

Sep 15, 2025, 1:39 PM EDT - 2 months ago

FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin

Sep 15, 2025, 8:00 AM EDT - 2 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Aug 22, 2025, 2:41 PM EDT - 3 months ago

Krystal Biotech: A "Strong Buy" Despite KB707 Melanoma Tumor Targeting Update

Aug 21, 2025, 12:11 PM EDT - 3 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 4, 2025, 12:42 PM EDT - 4 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:43 AM EDT - 4 months ago

Krystal (KRYS) Q2 Profit Jumps 143%

Jul 25, 2025, 9:00 AM EDT - 4 months ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 24, 2025, 8:00 AM EDT - 4 months ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 9, 2025, 7:00 AM EDT - 5 months ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jun 28, 2025, 9:10 AM EDT - 5 months ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

BEAM CERT INSP LFMD OPCH PODD TEM

Jun 24, 2025, 7:00 AM EDT - 5 months ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

May 7, 2025, 8:00 AM EDT - 7 months ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 2:43 PM EDT - 7 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 7:00 AM EDT - 7 months ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 24, 2025, 8:00 AM EDT - 8 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 7, 2025, 4:30 PM EDT - 8 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Mar 24, 2025, 8:30 AM EDT - 9 months ago

Krystal Biotech: Preparing To Chase Following Positive CHMP Opinion For VYJUVEK

Feb 28, 2025, 7:40 AM EST - 9 months ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 21, 2025, 8:15 AM EST - 10 months ago

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Feb 19, 2025, 11:43 AM EST - 10 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:00 AM EST - 10 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 10:20 AM EST - 10 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jan 14, 2025, 8:00 AM EST - 11 months ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 27, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 3:31 PM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Oct 14, 2024, 4:58 PM EDT - 1 year ago

Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 8:10 PM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 11:13 PM EDT - 1 year ago

Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)

Jul 26, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

May 15, 2024, 8:08 AM EDT - 1 year ago

Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB

May 15, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 8:00 AM EDT - 1 year ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 2, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 26, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 22, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 4, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO MREO TAK WVE

Iightning Dec. 4 at 4:57 AM

1ightning® Premium Options Alert (Actionable) Ticker: $KRYS Contract: Dec 19 $220C Entry: 5.80 Exit: 9.78 Return: +68.70% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 3 at 9:12 AM

1ightning® Premium Options Alert (Actionable) Ticker: $KRYS Contract: Dec 19 $270C Entry: 4.17 Exit: 5.80 Return: +38.90% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

macroaxis Dec. 3 at 12:25 AM

0 · Reply

Iightning Dec. 1 at 11:10 PM

0 · Reply

Ortho91 Nov. 28 at 12:12 PM

$KRYS rock on 🤘🏻

0 · Reply

Iightning Nov. 26 at 1:58 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:03 PM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 12:59 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $220 Call | Enter: $7.33 Exit: $10.60 | Profit: 44.69% ROI | https://1ightning.com

0 · Reply

PolycarpFX Nov. 24 at 10:11 PM

Red Mile Group's latest holdings, one of the best biotech firms in the world I’ll be releasing my quarterly Biotech Report this week via my newsletter. $SRRK $KRYS $ZYME $IDYA

0 · Reply

Ortho91 Nov. 22 at 10:47 PM

$KRYS shorts are down 48% since 9/25🤣

0 · Reply

BEATOFtheMARKET Nov. 22 at 9:27 PM

$KORU $KRMN $KRYS $KSS $KTOS

0 · Reply

Swifty_11 Nov. 22 at 1:45 AM

$KRYS https://www.gurufocus.com/news/3218711/krystal-biotech-krys-secures-fda-orphan-status-for-haileyhailey-treatment

0 · Reply

Iightning Nov. 21 at 10:16 PM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $210 Call | Enter: $8.78 Exit: $14.73 | Profit: 67.83% ROI | https://1ightning.com

0 · Reply

ZManicItalian Nov. 21 at 5:48 PM

$KRYS 🍻 to all the long time bulls here. Special shout out to @JFais for writing on this company back around the IPO!

1 · Reply

Iightning Nov. 21 at 1:31 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $210 Call | Enter: $8.78 Exit: $14.73 | Profit: 67.83% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 10:55 PM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $210 Call | Enter: $8.78 Exit: $14.73 | Profit: 67.83% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 7:13 AM

1ightning® Options Trade Alert (Actionable) | Buy $KRYS Dec 19 $210 Call | Enter: $8.78 Exit: $14.73 | Profit: 67.83% ROI | https://1ightning.com

0 · Reply

SweepCastApp Nov. 17 at 11:20 PM

$KRYS: Unusual Options Activity Alerted CALL flow observed 5x contracts at Strike price of $145 Exp on 11/21/2025 with Premium of $32K and showing BEARISH Sentiment

0 · Reply

Ortho91 Nov. 15 at 1:18 AM

$KRYS 🔥🔥🔥 This is going to be dangerously to continue shorting!!! Stay strong and tune out

0 · Reply

Quantumup Nov. 12 at 7:43 PM

Stifel trimmed⬇️ $ABEO's PT to $19 from $20 and reiterated at a Buy rating. $KRYS Here's what Stifel had to say in its note:

0 · Reply

ZManicItalian Nov. 12 at 5:02 PM

$KRYS 🤑🤙

0 · Reply

MaverikIT Nov. 12 at 3:09 PM

$VKTX $CNC $GRAL $KRYS $CDTX ...

0 · Reply

Market Cap	6.24B
Revenue (ttm)	290.52M
Net Income (ttm)	89.16M
EPS (ttm)	N/A
PE Ratio	32.25
Forward PE	34.81
Profit Margin	30.69%
Debt to Equity Ratio	0.00

Volume	240,200
Avg Vol	293,510
Day's Range	N/A - N/A
Shares Out	29.00M
Stochastic %K	77%
Beta	0.48
Analysts	Strong Sell
Price Target	$223.89